CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Peptide innovator says the drug class is due for a rethink

Neutral
AI Analysis

Summary

Sethera Therapeutics CEO Karsten Eastman discusses the evolving peptide drug class and advancements in peptide therapeutics from innovation through commercialization.

Importance:1/10
Sentiment:
0.00
peptide_therapeuticsinnovationdrug_classexecutive_perspective

Read the original article

Published by Pharmaceutical Technology on September 2, 2026 11:05 AM

Read Original